BlackRock Advisors’s Heron Therapeutics HRTX Stock Holding History

BlackRock Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$217K	Sell	16,567 -683	-4%	-$10.7K	﹤0.01%	2679
2016 Q3	$297K	Buy	17,250 +2,146	+14%	+$39.8K	﹤0.01%	2459
2016 Q2	$273K	Buy	15,104 +1,769	+13%	+$34.5K	﹤0.01%	2457
2016 Q1	$253K	Sell	13,335 -2,641	-17%	-$52.1K	﹤0.01%	2442
2015 Q4	$427K	Sell	15,976 -2,786	-15%	-$74.5K	﹤0.01%	2173
2015 Q3	$458K	Buy	18,762 +2,550	+16%	+$85K	﹤0.01%	2256
2015 Q2	$505K	Buy	16,212 +3,494	+27%	+$65.7K	﹤0.01%	2175
2015 Q1	$185K	Buy	12,718 +1,993	+19%	+$22.5K	﹤0.01%	2720
2014 Q4	$108K	Buy	10,725 +1,490	+16%	+$12.2K	﹤0.01%	3002
2014 Q3	$77K	Buy	9,235 +1,086	+13%	+$10.1K	﹤0.01%	3133
2014 Q2	$100K	Buy	+8,149	New	+$97.3K	﹤0.01%	3053

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

BlackRock Advisors's HRTX Position: Q4 2016 in Review

BlackRock Advisors reduced its Heron Therapeutics (HRTX) stake by 4% in Q4 2016, selling an estimated $10.7K and leaving 16,567 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #2679.

BlackRock Advisors first reported a position in HRTX in Q2 2014 and has held it in 11 quarters since. The position peaked at $505K in Q2 2015. 99 funds tracked by Wall St. Rank hold HRTX as of Q4 2016.

BlackRock Advisors held 16,567 shares of Heron Therapeutics worth $217K as of Q4 2016.
BlackRock Advisors sold 683 Heron Therapeutics shares in Q4 2016, an estimated $10.7K.
Heron Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2679 holding.
BlackRock Advisors first reported a position in Heron Therapeutics in Q2 2014 and has held it in 11 quarters since.
BlackRock Advisors's Heron Therapeutics position peaked at $505K in Q2 2015.
99 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.